Press Releases

Press Releases

November 7, 2018
CytomX to Present at the Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present
Additional Formats
November 6, 2018
CytomX Therapeutics Announces Third Quarter 2018 Financial Results
ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept  Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029  CX-188 IND Filing Marks Fifth Probody Therapeutic to Advance in Clinical Development  Company to Host a Conference Call Today at
Additional Formats
October 30, 2018
CytomX Therapeutics to Announce Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, plans to
Additional Formats
October 8, 2018
CytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting
Update from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab SOUTH SAN FRANCISCO, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel
Additional Formats
September 25, 2018
CytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced
Additional Formats
August 7, 2018
CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

Additional Formats
Displaying 1 - 10 of 26